TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Interference in pregnancy progress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Delayed toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Average number of interactions with mobile app
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average number of responses to prompts from mobile app
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived usefulness of mSMART app
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Autonomic dysfunction in children with epilepsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Procedure related adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis accuracy of superficial endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: World Health Organisation- Five Well-Being Index (WHO-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Efficacy for Exercise
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 36-Item Short Form Health Survey (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dinamometry measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Consumption - Drinking pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood samples - Presence of Inflammatory Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of CBD consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post procedure complications
Endpoint domain: Adverse events/effects
Primary endpoint: GERD-HRQL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Optic Nerve Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence of tumour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Performance of TREAT-B score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of WHO simplified score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of REACH-B score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects with Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of accurate diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective level of cognitive load
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of vertigo symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mayo Endoscopic Subscore of ≤ 1 point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Speed of improvement of the 4AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in patient motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the diagnostic device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the diagnostic device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of precuneus activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of days participants live at home
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Development of peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sleep Function
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: App Engagement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Daily stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Antitumor activity of SYHX1903 by overall response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fusion failure
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with effective rapid pacing run
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of the Clavien Dindo surgical score
Endpoint domain: Adverse events/effects
Primary endpoint: Hand dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of participants taking lipid-lowering medication regularly
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of recurrent genital herpes infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: SARS-Cov-2 antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hypertension Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of new Gadolinium-enhancing T1-hyperintense lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change from Baseline in MADRS-10
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in relative abundance of proteobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of high-quality physiological signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Reproducible changes in physiological biosignals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-care of the patient with IBD
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Self-care of the caregiver
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Dyadic interaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Evaluation of autonomy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Unified Parkinson's disease rating scale (MDS-UPDRS), section VI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With at Least One Post-dose Markedly Abnormal Value (MAV) in Laboratory Test
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With at Least One Post-dose MAV for Vital Signs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With at Least One Post-dose MAV for Electrocardiogram (ECG) Parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Emergence Agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autonomy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Procedural timings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Responders at Week 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of complement proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Alveolar-arterial difference in oxygen tension (A-aDO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lymphocyte populations and subpopulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MDSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from BSL in WORC Physical Symptom Domain score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to undetectable ENG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under concentration time curve (AUC 0-28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and percentage of patients experiencing CAD specific outcomes at 30 days after TAVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number and percentage of patients experiencing CAD specific outcomes at 3 months after TAVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number and percentage of patients with Device success at 30 days after TAVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number and percentage of patients free from Device safety issues at 30 days after TAVI
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of dose interruptions and dose reductions
Endpoint domain: Adverse events/effects
Primary endpoint: Solicited adverse events, graded by severity
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of major bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of thromboembolic events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects achieving ACR50 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metformin AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in enhancement time intensity curves obtained from CE-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Whole-Organ Magnetic Resonance Scoring (WORMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with 50% reduction in pain scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of adverse events associated with GAE
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Visual Analog Scale scores - heel tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analog Scale scores - first step pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Foot Function Index (FFI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health related Quality of Life (HRQOL) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical Activity Scale for the Elderly (PASE) scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Survival time (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Freedom from Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration of high-density lipoprotein cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Epilepsy Knowledge, Attitudes, and Practices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: overall score of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in monocular and binocular uncorrected near visual acuity (UNVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event (AEs) / complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the severity of posttraumatic stress disorder symptom total score from baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival at 6 months (PFS6)
Endpoint domain: Mortality/survival
Primary endpoint: patients' injection experiences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: satisfaction with the syringes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 4-month mean weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 12-month mean weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of muscle condition using ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients achieving response (complete and partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day 1 pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average overnight supine blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: effect on general condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apneic oxygenation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: The rate of Anxiety symptoms (HADS-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The rate of Depression symptoms (HADS-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The changes of Blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of children with ≥ 50% reduction in clinical spasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of asthma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of COPD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of respiratory symptoms related to long COVID
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety and adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: vasovagal reaction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of peripheral vascular diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in Physical Activity Levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Abnormal pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Abnormal cardiovascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Abnormal quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: serum CGRP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Centration of the IOL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in ambulatory 24-hour average SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in number of standard drinks past week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilator days with lung-protective ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline on MADRS total scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Degree of difficulty in intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Percentage of Participants with Serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Percentage of Participants with Grade 3 or Higher TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of reported cardiac arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of reported hospital admission with heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of reported hospital admission with acute myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient provider experience survey score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Provider experience survey score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of in-patient encounters with COVID patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in weekly mean 24-hour average NRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rivermead Extended Activities of Daily Life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Memory and Concentration Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frenchay Activities Index
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: WAL-K test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of TVC test to predict early post-operative AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Diagnostic efficiency of tracers in sentinel lymph node detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence of positive viral PCR assays
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevention of diabetic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression pattern of COMMD7 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acceptability of the decision aid tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modified Yorkshire COVID-19 scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in brain waves from before and after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in impulsivity from treatment using Barratt Impulsiveness Scale (BIS-11)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Side effects or adverse events from the study device using vitals signs
Endpoint domain: Adverse events/effects
Primary endpoint: Past-month alcohol problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Past-month posttraumatic stress symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Past-month provisional diagnosis of posttraumatic stress disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Timed Up & Go (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 75-g Oral Glucose Tolerance Test (120 minute glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Foot Care Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Short-form 12-items (SF-12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perceived stress score 10-item measure (PSS-10)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline general development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenoma and polyp miss rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Weekly changes of Patient Health Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Weekly changes of Chinese Perceived Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment success from pulse field ablation treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of obtaining samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCF levels of IL-39 & IL35
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delirium incidence as measured by the 3D-CAM
Endpoint domain: Adverse events/effects
Primary endpoint: Delirium incidence as measured by the CAM ICU
Endpoint domain: Adverse events/effects
Primary endpoint: Delirium severity as measured by the CAM ICU
Endpoint domain: Adverse events/effects
Primary endpoint: Projected aortic valve area (AVAproj)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wound healing score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Montreal Cognitive Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: hemoglobin A1c values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body Weight Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Reporting One or More Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Peripheral muscle strength measured by hand held dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes